Excerosis

Clinical Neuroscience

Volumn 3, Issue 6, 1995, Pages 348-359

  Rothstein, Jeffrey D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Combination therapy; EAAC1; Excitotoxicity; GLAST; GLT 1; Glutamate transport; Metabolism

Indexed keywords

EXCITOTOXIN; GLUTAMIC ACID;

AMINO ACID METABOLISM; AMINO ACID TRANSPORT; AMYOTROPHIC LATERAL SCLEROSIS; HUMAN; MOTONEURON; NERVE CELL EXCITABILITY; NERVE DEGENERATION; NEUROTRANSMITTER RELEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

AMYOTROPHIC LATERAL SCLEROSIS; GLUTAMIC ACID; HUMANS; NERVE DEGENERATION; NEUROTRANSMITTER AGENTS;

EID: 0029435316     PISSN: 10656766     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Asmark H, Aquilonius SM, Gillberg PG, Liedholm LJ, Stâlberg E, Wuopio R (1993): A pilot trial of dextromethorphan in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 56:197-200.
2. Bakshi R, Ni RX, Faden AI (1992): N-MethylD-aspartate (NMDA) and opiod receptors mediate dynorphin-induced spinal cord injury: Behavioral and histological studies. Brain Res 580:255-264.
3. Barbour B, Szatkowski, Ingledew N, Attwell (1989): Arachidonic acid induces a prolonged inhibition of glutamate uptake into glial cells. Nature 342:918-920.
4. Bargett ME, Heritage RL, Harding J, Brenner DM, Csernansky JG (1994): Accumulation of extracellular excitatory amino acids after glutamate uptake inhibition: An in vivo microdialysis study of the ventral striatum. Soc Neurosci Abs 20: 926.
5. Bensimon G, Lacomblez L, Meininger V, and the ALS/Riluzole Study Group (1994): A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 330:585-591.
6. Bowling AC, Schultz, JB, Brown RB, Beal MF (1993): Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 61:2322-2325.
7. Bridges RJ, Hatalski C, Shim SN, Nunn PB (1991): Gliotoxic properties of the Lathyms excitotoxin -N-oxalyl-L-a,-diaminopropionic acid (-L-ODAP). Brain Res 561:262-268.
8. Camu W, Billiard M, Baldy-Moulinier M (1993): Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: A subtype analysis. Acta Neurol Scand 88:51-55.
9. Chan PH, Kerlan R, Fishman RA (1983): Reductions of y-aminobutyric acid and glutamate uptake and (Na+ + K+)ATPase activity in brain slices and synaptosomes by arachidonic acid. J Neurochem 40:309-316.
10. Choi DW, Rothman SM (1990): The role of glutamate neurotoxicity in hypoxicischemic neuronal death. Annu Rev Neurosci 13:171-182.
11. Choi DW (1988): Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623-634.
12. Corse AM, Kuncl RW, Rothstein JD (1993): Neuroprotective neurotrophic factors in a model of chronic glutamate toxicity. Ann Neurol 34:304 (abst).
13. Couratier P, Hugon J, Sindou P, Vallat JM, Dumas M (1993): Cell culture evidence for neuronal degeneration in amyotrophic lateral sclerosis being linked to glutamate AMPA/kainate receptors. Lancet 341:265-268.
14. Couratier P, Sindou P, Esclaire F, Louvel E, Hugon J (1994): Neuroprotective effects of riluzole in ALS CSF toxicity. Neuropharm Neurotoxicol 5:1012-1014.
15. Coyle JT, Puttfarcken P (1993): Oxidative stress, glutamate, and neurodegenerative disorders. Science 262:689-695.
16. Danbolt NC, Storm-Mathisen J, Kanner BI (1992): An [Na+ + K+]coupled L-glutamate transporter purified from rat brain is localized in glial cell processes. Neuroscience 51:295.
17. Eisen AN, Steward H, Schulzer M, Cameron D (1993): Anti-glutamate therapy in amyotrophic lateral sclerosis: A trial using lamotrigine. J Can Sei Neurol 20:297-301.
18. Ferrarese C, Pecora N, Frigo M, Appollonio I, Frattola L (1993): Assessment of reliability and biological significance of glutamate levels in cerebrospinal fluid. Ann Neurol 33:316-319.
19. Fletcher EJ, Martin D, Aram JA, Lodge D, Honoré T. (1988): Quinoxalinediones selectively block quisqualate and kainate receptors and synaptic events in rat neocortex and hippocampus and frog spinal cord in vitro. Br J Pharmacol 95:585-597.
20. Fonnum F, Paulsen RE (1990): Comparison of transmitter amino acid levels in rat globus pallidus and neostriatum during hypoglycemia or after treatment with methionine sulfoximine or gammavinyl gamma-aminobutyric acid. J Neurochem 54:1253-1257.
21. Foster AC (1991): Channel blocking drugs for the NMDA receptor. In Meldrum BS (ed): Excitatory Amino Acid Antagonists. Oxford: Blackwell Scientific, pp 164-179.
22. Hertz L (1979): Functional interactions between neurons and astrocytes. I. Turnover and metabolism of putative amino acid transmitters. Prog Neurobiol 13:277-323.
23. Hollander D, Pradas J, Kaplan R, McLeod H, Evans W, Munsat T (1992): Longterm high-dose dextromethorphan in amyotrophic lateral sclerosis. Ann Neurol 32:280.
24. Hollmann M, Heinemann S (1994): Cloned glutamate receptors. Annu Rev Neurosci 17:31-108.
25. Hösli L, Hösli E, Lehmann R, Eng P (1983): Effects of the glutamate analogue AMPA and its interaction with antagonists on cultured rat spinal and brain stem neurones. Neurosci Lett 36:59-62.
26. Hugon J, Tabaraud F, Rigaud M, Vallat JM, Dumas M (1989): Glutamate dehydrogenase and aspartate aminotransferase in leukocytes of patients with motor neuron disease. Neurology 39:956-958.
27. Huntley GW, Vickers JC, Janssen W, Brose N, Heinemann SF, Morrison JH (1994): Distribution and synaptic localization of immunpcytochemically identified NMDA receptor subunit proteins in sensory-motor and visual cortices of monkey and human. J Neurosci 14:36033619.
28. Iwasaki Y, Ikeda K, Kinoshita M (1992): Plasma amino acid levels in patients with amyotrophic lateral sclerosis. ] Neurol Sei 107:219-222.
29. Iwatsuji K, Nakamura S, Kameyama M (1989): Lymphocyte glutamate dehydrogenase activity in normal aging and neurological diseases. Gerentology 35: 218-224.
30. Jansen KLR, Faull RLM, Dragunow M, Waldvogel H (1990): Autoradiographic localisation of NMDA, quisqualate and kainic acid receptors in human spinal cord. Neurosci Lett 108:53-57.
31. Kalb RG, Lidow MS, Halsted MJ, Hockfeld S (1992): N-Methyl-D-aspartate receptors are transiently expressed in the developing spinal cord ventral horn. Proc Natl Acad Sei USA 89:8502-8506.
32. Kanai Y, Hediger MA (1992): Primary structure and functional characterization of a high-affinity glutamate transporter. Nature 360:467-471.
33. Krogsgaard-Larsen P, Ferkany JW, Nielsen EO, Madesn U, Ebert B, Johansen JS, Diemer NH, Bruhn T, Beattie DT, Curtis DR. (1991) Novel class of amino acid antagonists at non-N-methyl-D-aspartatic acid excitatory amino acid receptors. Synthesis, in vitro and in vivo pharmacology, and neuroprotection. J Med Chem 34:123-130.
34. Lin G, Bristol LA, Rothstein JD (1996). An abnormal mRNA leads to down regulation of glutamate transporter EAAT2 (GLT-1) expression in familial amyotrophic lateral sclerosis. Ann Neurol. 40: 540-541.
35. Long JB, Rigamonti DD, Oleshansky MA, Wingfield DP, Martinez-Arizala A (1994): Dynorphin A-induced rat spinal cord injury: Evidence for excitatory amino acid involvement in a pharmacological model of ischémie spinal cord injury. J Pharm Exp Ther 269:358-366.
36. Malessa S, Leigh PN, Bertel O, Sluga E, Hornykiewicz O (1991): Amyotrophic lateral sclerosis: Glutamate dehydrogenase and transmitter amino acids in the spinal cord. J Neurol Neurosurg Psychiatry 54:984-988.
37. Martin LJ, Blackstone CD, Levey AI, Huganir RL, Price DL (1994): AMPA glutamate receptor subunits are differentially distributed in rat brain. Neuroscience 53:327-358.
38. Meldrum B, Garthwaite J (1991): Excitatory amino acid neurotoxicity and neurodegenerative disease. In Lodge D, Collingridge GL (eds): The Pharmacology of Excitatory Amino Acids. Cambridge: Elsevier, pp 54-61.
39. Mentis GZ, Greensmity L, Vrbova G (1993): Motor neurons destined to die are rescued by blocking N-Methyl-D-aspartate receptors by MK-801. Neuroscience 54:283-285.
40. Michikavva M, Lim KT, McLarnon JG, Kim SU (1993): Oxygen radical-induced neurotoxicity in spinal cord neuron cultures. J Neurosci Res 37:62-70.
41. Miller RG, Moore D, Young BS, Armon C, Barohn RJ, Bromberg MB, Bryan WW, Gelinas DF, Medoza RPT, Neville HE, Parry GJ, Petajan JH, Ravits JM, Ringel SP, Ross MA, and the WALS Study Group. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis (ALS). Neurology, in press.
42. Olney JW (1969): Brain lesions, obesity and other disturbances in mice treated with monosodium glutamate. Science 164: 719-721.
43. Perry-TL, Bergeron C, Steele JC, McLachlan DR, Hansen S (1990): Brain amino acid 'contents are dissimilar in sporadic and Guamanian amyotrophic lateral sclerosis. J Neurol Sei 99:3-8.
44. Perry TL, Hansen Sh, Jones K (1987): Brain glutamate deficiency in amyotrophic lateral sclerosis. Neurology 37:1845-1848.
45. Petralia RS, Yokotani N, Wenthold RJ (1994): Light and electron microscope distribution of the NMDA receptor subunit NMDAR1 in the rat nervous system using a selective anti-peptide antibody. J Neurosci 14:667-696.
46. Pines G, Danbolt NC, Bjoras M, Zhang Y, Bendahan A, Eide L, Koepsell H, StormMathisen J, Seeberg E, Kanner BI (1992) Cloning and expression of a rat brain L-glutamate transporter. Nature 360: 464.
47. Plaitakis A (1988): A trial of branched chain aminoacids in amyotrophic lateral sclerosis. Lancet 1:1015-1018.
48. Plaitakis A (1990): Glutamate dysfunction and selective motor neuron degeneration in amyotrophic lateral sclerosis: A hypothesis. Ann Neurol 28:3-8.
49. Plaitakis A, Caroscio JT (1987): Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol 22:575-579.
50. Plaitakis A Constantakakis E, Smith J (1988): The neuroexcitotoxic amino acids glutamate aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis. Ann Neurol 24:446449.
51. Plaitakis A, Constantakakis E (1993): Altered metabolism of excitatory amino acids, N-acetyl-aspartate and N-acetylaspartyl-glutamate in amyotrophic lateral sclerosis. Brain Res 30:381-386.
52. Pogun S, Davvson V, Kuhar M (1994): Nitric oxide inhibits 3H-glutamate transport in synaptosomes. Synapse 18:21-26.
53. Pruss RM, Akeson RL, Racke MM, Wilburn JL (1991): Agonist-activated cobalt uptake identifies divalent cation-permeable kainate receptors on neurons and glial cells. Neuron 7:509-518.
54. Rothstein JD, Kuncl RW (1995): Neuroprotective stratagies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem 65:643-651.
55. Rothstein JD, Tabakoff B (1984): Alteration of striatal glutamate release after glutamine synthetase inhibition. J Neurochem 43:1438-1446.
56. Rothstein JD, Tsai G, Kuncl RW, Clawson L, Cornblath DR, Drachman DB, Pestronk A, Stauch BL, Coyle T (1990): Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 28:15-25.
57. Rothstein JD, Kuncl R, Chaudhry V, Clawson L, Cornblath DR, Coyle JT, Dachman DB (1991) Excitatory amino acids in ALS: An update [letter]. Ann Neurol 31:449-450.
58. Rothstein JD, Martin LJ, Kuncl RW (1992): Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 22:14641468.
59. Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW (1993): Chronic glutamate uptake inhibition produces a model of slow neurotoxicity. Proc Natl Acad Sei USA 90:6591-6595.
60. Rothstein JD, Bristol LA, Hosier B, Brown RH, Kuncl RW (1994a): Chronic inhibition of Superoxide dismutase produces apoptotic death of spinal neurons. Proc Natl Acad Sei USA 91:4155-5159.
61. Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, Kanai Y, Hediger M, Wang Y, and Welty DF (1996): Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16:675-686.
62. Rothstein JD, Martin L, Levey AI, DykesHoberg M, Jin L, Wu D, Nash N, Kuncl RW (1994c): Localization of neuronal and glial glutamate transporters. Neuron 13:713-725.
63. Rothstein JD, Van Kämmen M, Levey AI, Martin L, Kuncl RW (1995): An analysis of glutamate transporter subtypes in amyotrophic lateral sclerosis: A selective loss of glial glutamate transporter GLT-1. Ann Neurol 38:73-84.
64. Shank RP, Campbell GL, Freytah SO, Utter MF (1981): Evidence that pyruvate carboxylase is an astrocyte specific enzyme. Soc Neurosci Abs 7:936.
65. Shank RP, Campbell GL (1984): ct-Ketoglutarate and malate uptake and metabolism by synaptosomes. Further evidence for an astrocytes-to-neuron metabolic shuttle. JNeurochem 42:11531161.
66. Shaw PJ (1994): Excitotoxicity and motor neuron disease: A review of the evidence. J Neurol Sei 124(suppl):6-13.
67. Shaw PJ, Ince PG, Johnson M, Perry EK, Candy J (1991): The quantitative autoradiographic distribution of [3H]MK-801 binding sites in the normal human spinal cord. Brain Res 539:164-168.
68. Shaw PJ, Ince PG, Johnson M, Perry EK, Candy JM (1992): The quantitative autoradiographic distribution of [3H]MK801 binding sites in the normal human brainstem in relation to motor neuron disease. Brain Res 572:276-280.
69. Shaw PJ, Chinnery RM, Ince PG (1994a): [3H]D-Aspartate binding sites in the normal human spinal cord and changes in motor neuron disease: A quantitative autoradiographic study. Brain Res 655: 195-201.
70. Shaw PJ, Ince PG, Matthews JNS, Johnson M, Candy JM (1994b): N-Methyl-Daspartate (NMDA) receptors in the spinal cord and motor cortex in motor neuron disease: A quantitative autoradiographic study using [3H]MK-801. Brain Res 637:297-302.
71. Spink DC, Swann JW, Snead OC, Waniewski RA, Martin DL (1986): Analysis of aspartate and glutamate in human cerebrospinal fluid by high-performance liquid chromatography with automated precolumn derivatization. Anal Biochem 158:79-86.
72. Stewart GR, Olney JW, Pathikonda M, Snider WD (1991) Excitotoxicity in the chick spinal cord. Ann Neurol 30:758766.
73. Storck T, Schulte S, Hofmann K, Stoffel W (1992): Structure, expression, and functional analysis of a Na(+)-dependent glutamate/aspartate transporter from rat brain. Proc Natl Acad Sei USA 89:10955-10959.
74. Tandan R, Bromberg MB, Fries TJ, Fillyaw MJ, Betts E, Nau K, Forshew D, Krusinski PB, Carpenter J, Badger G (1994): Controlled treatment trial with amino
75. acids in amyotrophic lateral sclerosis. Neurology 44(suppl 2):A166.
76. Testa D, Carceni T, Fetoni V (1989): Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis. J Neurol 236:445-447.
77. Tolle TR, Berthele A, Zieglgansberger VV, Seeburg PH, Wisden W (1993): The differential expression of 16 NMDA and non-NMDA receptor subunits in the rat spinal cord and in periaqueductal gray. J Neurosci 13:5009-5028.
78. Tsai G, Stauch-Slusher B, Sim L, Hedreen JC, Rothstein JD, Kuncl RW, Coyle JT (1991): Reductions in acidic amino acids and N-acetylaspartylglutamate in amyotrophic lateral sclerosis central nervous system. Brain Res 556:151-156.
79. Volterra A, Trotti D, Cassutti P, Troma C, Salvaggio A, Melcangi RC, Racagni G .(1992): High sensitivity of glutamate uptake to extracellular free arachidonic acid levels in rat cortical synaptosdmes and astrocytes. J Neurochem 59:600606.
80. Volterra A, Trotti D, Troma C, Floridi S, Racagni G (1994): Glutamate uptake inhibition by oxygen free radicals in rat cortical astrocytes. J Neurosci 14:29242932.
81. von Euler M, Siegler A, Holmberg L, Sundstrom E (1994): NBQX, a competitive non-NMDA receptor antagonist, reduces degeneration due to focal spinal cord ischemia. Exp Neurol 129:163168.
82. Wang GJ, Qin YQ, Price MT, OIney JW (1991): Homocysteate, kainate and AMPA induce spinal cord lesions when administered subcutaneously to infant rats. Soc Neurosci Abs 17:787.
83. Welty DF, Schielke GP, Rothstein JD (1995): Potential treatment of amyotrophic lateral sclerosis by the anticonvulsant gabapentin: a hypothesis. Ann Pharmacotherapy 29:1164-1167.
84. Yum SW, Faden AI (1990): Comparison of the neuroprotective effects of the N-Methyl-D-aspartate antagonists MK801 and the opiate-receptor antagonist nalmefene in experimental spinal cord ischemia. Arch Neurol 46:277-281.
85. Zeman S, Lloyd C, Meldrum B, Leigh PN (1994): Excitatory amino acids, free radicals and the pathogenesis of motor neuron disease. Neuropathol Appl Neurobiol 20:219-231.
86. Ziskind-Conhaim L (1990): NMDA receptors mediate poly- and monosynaptic potentials in motoneurons of rat embryos. J Neurosci 10:125-135.